Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
KM Biologics Co Ltd
Lee's Pharmaceutical Holdings Ltd
Sanofi
TagCyx Biotechnologies
Takeda Pharmaceutical Co Ltd
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
apadamtase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
caplacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAGX-0004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
Featured News & Press Releases
Apr 30, 2020: CHMP adopts positive opinion for treatment of acquired thrombotic thrombocytopenic purpura with caplacizumab
Mar 02, 2020: Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Dec 17, 2019: Sanofi wins prestigious drug discovery award for innovative Rare Blood Clotting Disorder treatment
Nov 06, 2019: New data on Cablivi to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders
Mar 21, 2019: Biologics by McKesson expands specialty pharmacy capabilities to serve patients with rare and complex conditions
Feb 07, 2019: FDA approves Sanofi’s Cablivi as first therapy for rare blood disorder
Jan 09, 2019: New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder
Oct 30, 2018: Pharm-Olam conducts pivotal orphan disease trial, leads to first therapeutic approved for the treatment for acquired thrombotic thrombocytopenic purpura
Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
Sep 03, 2018: Sanofi’s Cablivi receives EC approval to treat rare blood disorder
Jun 29, 2018: Sanofi: CHMP recommends approval of Cablivi (caplacizumab)
Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab
Dec 12, 2017: Ablynx Reports Additional Clinically Important Benefits of Caplacizumab From its Phase III Hercules Study in Acquired TTP
Dec 07, 2017: Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following Ash Late-Breaking Data Presentation
Nov 21, 2017: Results From the Phase III Hercules Study of Caplacizumab for the Treatment of Acquired TTP Selected For Presentation In The Late-Breaking Abstracts Session at The 2017 Ash Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
KM Biologics Co Ltd
Lee's Pharmaceutical Holdings Ltd
Sanofi
TagCyx Biotechnologies
Takeda Pharmaceutical Co Ltd
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
apadamtase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
caplacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAGX-0004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
Featured News & Press Releases
Apr 30, 2020: CHMP adopts positive opinion for treatment of acquired thrombotic thrombocytopenic purpura with caplacizumab
Mar 02, 2020: Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)
Dec 17, 2019: Sanofi wins prestigious drug discovery award for innovative Rare Blood Clotting Disorder treatment
Nov 06, 2019: New data on Cablivi to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders
Mar 21, 2019: Biologics by McKesson expands specialty pharmacy capabilities to serve patients with rare and complex conditions
Feb 07, 2019: FDA approves Sanofi’s Cablivi as first therapy for rare blood disorder
Jan 09, 2019: New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder
Oct 30, 2018: Pharm-Olam conducts pivotal orphan disease trial, leads to first therapeutic approved for the treatment for acquired thrombotic thrombocytopenic purpura
Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
Sep 03, 2018: Sanofi’s Cablivi receives EC approval to treat rare blood disorder
Jun 29, 2018: Sanofi: CHMP recommends approval of Cablivi (caplacizumab)
Dec 21, 2017: Ablynx Announces Positive Data From Its Japanese Ethno-Bridging Study Of Caplacizumab
Dec 12, 2017: Ablynx Reports Additional Clinically Important Benefits of Caplacizumab From its Phase III Hercules Study in Acquired TTP
Dec 07, 2017: Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following Ash Late-Breaking Data Presentation
Nov 21, 2017: Results From the Phase III Hercules Study of Caplacizumab for the Treatment of Acquired TTP Selected For Presentation In The Late-Breaking Abstracts Session at The 2017 Ash Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TagCyx Biotechnologies, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, H2 2020
Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by TagCyx Biotechnologies, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, H2 2020
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
